Skip to main content
4DMEDICAL LIMITED logo

4DMEDICAL LIMITED — Investor Relations & Filings

Ticker · 4DX ISIN · AU0000095416 LEI · 9845000A8F12A6A6FD75 ASX Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 546 across all filing types
Latest filing 2024-02-27 Investor Presentation
Country AU Australia
Listing ASX 4DX

About 4DMEDICAL LIMITED

https://4dmedical.com/

4DMedical Limited develops non-invasive respiratory imaging solutions centered on its proprietary XV Technology. This platform utilizes advanced algorithms to transform standard X-ray sequences into four-dimensional quantitative data, visualizing regional lung function in motion. The flagship XV Lung Ventilation Analysis Software (XV LVAS) provides clinicians with detailed maps of airflow distribution throughout the respiratory cycle, facilitating the early detection and monitoring of chronic conditions such as COPD, asthma, and interstitial lung disease. By providing objective, high-resolution insights into lung ventilation without the limitations of traditional pulmonary function tests, the company's cloud-based diagnostic tools aim to improve clinical workflows and patient management. The integration of artificial intelligence further enhances its capability to deliver precise, automated lung tissue analysis.

Recent filings

Filing Released Lang Actions
1H FY2024 Investor Presentation 36 pages 4.4MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation by 4DMedical Limited dated around 28 February 2024, focusing on the company's half-year 2024 highlights, acquisition update, commercial updates, financials, management, and strategic outlook. It includes extensive discussion of the Imbio acquisition, revenue growth, product portfolio, commercial agreements, and clinical applications. The content is structured as a presentation with agenda points, charts, and strategic commentary, typical of an investor presentation. There is no indication that this is a full annual or interim report with comprehensive financial statements, nor is it a regulatory filing or announcement. The document is too long and detailed to be a simple announcement or report publication notice. Therefore, the best classification is Investor Presentation (IP).
2024-02-27 English
Imbio secures research agreement with US Dept of Vet Affairs 3 pages 214.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 27 February 2024 from 4DMedical Limited regarding a research agreement with the U.S. Department of Veterans Affairs. It details the nature of the research project, scientific aims, and company statements. There are no financial statements, earnings data, or regulatory filings such as annual or quarterly reports. The document is a corporate announcement about a new research collaboration, not a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a general corporate announcement about a research agreement, which aligns best with the category of Regulatory Filings (RNS) as a fallback for miscellaneous announcements that do not fit other categories.
2024-02-26 English
4DMedical signs distribution agreement with Blackford 2 pages 205.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 26 February 2024, describing a new distribution agreement between 4DMedical and Blackford for medical imaging AI solutions. It is a corporate news release about a partnership and business development, not a financial report, earnings release, or regulatory filing. There are no financial statements, management discussion, or regulatory compliance content. The document is a typical corporate announcement about a commercial agreement, which fits best under the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2024-02-25 English
Quarterly Activity Report and Appendix 4C for Q2 FY2024 11 pages 543.5KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Activity Report and Appendix 4C for Q2 FY2024' and dated 31 January 2024. It contains detailed financial performance data for the half-year period, including operating revenue, cash flows, and capital raising activities. It also discusses operational updates, acquisitions, commercial agreements, regulatory approvals (CMS reimbursement, FDA clearance), and strategic partnerships. The document is approximately 15,000 characters long, indicating it is a substantive report rather than a brief announcement. The presence of financial data, operational updates, and strategic commentary aligns with the characteristics of an Interim / Quarterly Report. The Appendix 4C is a cash flow report typically included in quarterly reporting for ASX-listed companies. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q2 2024
2024-01-30 English
Notification regarding unquoted securities - 4DX 8 pages 31.1KB
Share Issue/Capital Change Classification · 100% confidence The document is a notification regarding the issue of unquoted equity securities, specifically options issued under an employee incentive scheme. It details the number of securities issued, the dates, the recipients including key management personnel, and references shareholder approval at an Extraordinary General Meeting. The content focuses on the issuance of securities and related compliance with listing rules, without containing financial statements or performance data. This matches the definition of a Share Issue/Capital Change announcement, which covers new share issues or capital changes. The document length and detail confirm it is not a brief announcement of a report but a substantive notification of capital changes.
2024-01-23 English
Change of Director's Interest Notice 2 pages 281.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details a director's change in relevant interests in securities, including the number of shares and options held before and after the change, the nature of the interest, and the date of change. This type of document is a formal notification of personal share transactions by a company director. It does not contain financial performance data, management discussion, or other report content. Therefore, it fits the category of Director's Dealing (DIRS). The document length is 3787 characters, consistent with a detailed but concise notice of director share transactions.
2024-01-23 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.